Partnerships, M&A, clinical readouts, approvals and financing across pharma and biotech.https://pharmadigest.net/enhttps://pharmadigest.net/en/articles/2026-10-23-isomorphic-labs-valuation-ai-drug-discovery/https://pharmadigest.net/en/articles/2026-10-23-isomorphic-labs-valuation-ai-drug-discovery/STAT's AI Prognosis column asks what Isomorphic Labs' very high valuation says about AI's role in drug development. Separate reports describe early talks to raise new funds at a valuation of at least $40 billion, shortly after a roughly $2.1 billion round in May 2026; no financing has closed. The column also touches on the debate over AI and the cost of care.Fri, 23 Oct 2026 00:00:00 GMTIndustry NewsIsomorphic LabsAI drug discoveryvaluationfinancinghttps://pharmadigest.net/en/articles/2026-10-23-lilly-metis-ai-lnp-delivery-deal/https://pharmadigest.net/en/articles/2026-10-23-lilly-metis-ai-lnp-delivery-deal/Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies. METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model. Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.Fri, 23 Oct 2026 00:00:00 GMTIndustry NewsEli LillyMETiSlipid nanoparticlesAI drug deliverycollaborationhttps://pharmadigest.net/en/articles/2026-10-22-gsk-fda-approval-hepatitis-b-functional-cure/https://pharmadigest.net/en/articles/2026-10-22-gsk-fda-approval-hepatitis-b-functional-cure/STAT reports that GSK has won FDA approval for its hepatitis B drug. The drug extended functional cures to far more patients than previous methods, according to the report. Details beyond the headline were not available to us; the product is understood to be the antisense bepirovirsen.Thu, 22 Oct 2026 00:00:00 GMTIndustry NewsGSKhepatitis BFDA approvalantisense oligonucleotidefunctional curehttps://pharmadigest.net/en/articles/2026-10-22-roivant-positive-trial-non-infectious-uveitis/https://pharmadigest.net/en/articles/2026-10-22-roivant-positive-trial-non-infectious-uveitis/STAT reports that Roivant announced positive trial results for its immune drug in non-infectious uveitis. The result could open a new market for the drug beyond its current indications. Only the headline and lede were available to us; the specific endpoints and data are not confirmed here.Thu, 22 Oct 2026 00:00:00 GMTIndustry NewsRoivantnon-infectious uveitistrial resultimmunologyhttps://pharmadigest.net/en/articles/2026-10-22-roche-hansoh-adc-portfolio-collaboration/https://pharmadigest.net/en/articles/2026-10-22-roche-hansoh-adc-portfolio-collaboration/Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license. Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties. Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.Thu, 22 Oct 2026 00:00:00 GMTIndustry NewsRocheHansohADCChina licensingcollaborationhttps://pharmadigest.net/en/articles/2026-10-21-china-draft-curbs-foreign-biopharma-acquisitions/https://pharmadigest.net/en/articles/2026-10-21-china-draft-curbs-foreign-biopharma-acquisitions/China is proposing new restrictions on foreign acquisitions of critical biopharma technologies as it seeks to keep control of its fast-growing drug development industry. Trade coverage of the draft (Fierce) describes it as targeting full transfers of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, while standard out-licensing and CRO/CDMO outsourcing appear to be exempt. The final text and timing are not confirmed.Wed, 21 Oct 2026 00:00:00 GMTIndustry NewsChinaregulationM&Aexport controlcell and gene therapysiRNAhttps://pharmadigest.net/en/articles/2026-10-20-gilead-emvistegrast-swift-phase2-ulcerative-colitis/https://pharmadigest.net/en/articles/2026-10-20-gilead-emvistegrast-swift-phase2-ulcerative-colitis/Gilead's once-daily oral α4β7 integrin inhibitor emvistegrast (GS-1427) met its primary endpoint in the Phase 2 SWIFT study in ulcerative colitis. At the 200 mg dose, clinical remission at week 12 was roughly three times the placebo rate, with nominal significance and good tolerability. STAT's report is paywalled; figures here follow Gilead's own statement.Tue, 20 Oct 2026 00:00:00 GMTIndustry Newsulcerative colitisoralα4β7 integrinPhase 2https://pharmadigest.net/en/articles/2026-10-20-merck-kgaa-silence-therapeutics-acquisition/https://pharmadigest.net/en/articles/2026-10-20-merck-kgaa-silence-therapeutics-acquisition/Merck KGaA will acquire Silence in an all-cash deal at $20 per ADS, an equity value of about $1.3 billion, via a UK scheme of arrangement. The price is a 130% premium to the prior close, and Silence called it the outcome of a competitive sale process. The deal follows positive Phase 2 data for Silence's siRNA divesiran in polycythemia vera.Tue, 20 Oct 2026 00:00:00 GMTIndustry NewsM&AsiRNApolycythemia veraMerck KGaAhttps://pharmadigest.net/en/articles/2026-10-19-lilly-gate-bioscience-sec61-collaboration-expansion/https://pharmadigest.net/en/articles/2026-10-19-lilly-gate-bioscience-sec61-collaboration-expansion/Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M. The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones. Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.Mon, 19 Oct 2026 00:00:00 GMTIndustry NewsSec61partnershipsmall moleculeLillyhttps://pharmadigest.net/en/articles/2026-10-18-lakefront-armed-cell-car-t-programs-sale/https://pharmadigest.net/en/articles/2026-10-18-lakefront-armed-cell-car-t-programs-sale/Lakefront Biotherapeutics, the former Galapagos, is selling its abandoned cell therapy programs to Armed Cell Therapeutics, a new Belgian company co-founded and chaired by ex-Galapagos CEO Paul Stoffels. Reported terms are a small upfront payment (single-digit millions of euros) plus up to roughly $230 million in milestones. The package covers two armed CAR-Ts nearing the clinic in non-Hodgkin lymphoma and small cell lung cancer, plus three early preclinical projects.Sun, 18 Oct 2026 00:00:00 GMTIndustry NewsCAR-Tcell therapydivestitureGalapagosLakefronthttps://pharmadigest.net/en/articles/2026-10-17-revmed-rasonque-eu-approval-recommendation/https://pharmadigest.net/en/articles/2026-10-17-revmed-rasonque-eu-approval-recommendation/Following FDA approval, European regulators have recommended approval of Revolution Medicines' Rasonque (daraxonrasib) for pancreatic cancer, per STAT+. The recommendation moves the RAS(ON) inhibitor toward a second major market. This summary rests on the article's teaser; a separate search could not confirm the EU opinion.Sat, 17 Oct 2026 00:00:00 GMTIndustry NewsRevolution MedicinesdaraxonrasibRASpancreatic cancerEMAhttps://pharmadigest.net/en/articles/2026-10-17-astrazeneca-insitro-ai-target-discovery-deal/https://pharmadigest.net/en/articles/2026-10-17-astrazeneca-insitro-ai-target-discovery-deal/AstraZeneca and insitro signed a collaboration to find novel drug targets for liver and heart diseases using AI. Reported terms: a modest upfront payment of $40 million, with milestones taking the total to about $1.5 billion. Terms come from search-snippet reporting of the Fierce Biotech article, which could not be opened directly.Sat, 17 Oct 2026 00:00:00 GMTIndustry NewsAstraZenecainsitroAItarget discoveryliver diseasehttps://pharmadigest.net/en/articles/2026-10-17-merck-moderna-mrna-cancer-vaccine-keytruda-strategy/https://pharmadigest.net/en/articles/2026-10-17-merck-moderna-mrna-cancer-vaccine-keytruda-strategy/At the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li discussed pairing Keytruda with personalized mRNA cancer vaccines. Both executives framed the first positive results as a start, with much left to work out. This summary rests on the article's teaser, not the full text.Sat, 17 Oct 2026 00:00:00 GMTIndustry NewsMerckModernamRNAcancer vaccineKeytrudahttps://pharmadigest.net/en/articles/2026-10-16-verastem-vs-7375-kras-g12d-pancreatic/https://pharmadigest.net/en/articles/2026-10-16-verastem-vs-7375-kras-g12d-pancreatic/Verastem presented early results for its KRAS G12D inhibitor, studied in more than 200 patients with advanced solid tumors including metastatic pancreatic cancer and others. Other coverage describes anti-tumor activity and a manageable safety profile across pancreatic, colorectal and lung cancers. This summary rests on the public lead of a paywalled STAT piece plus secondary reports, so details are limited.Fri, 16 Oct 2026 00:00:00 GMTIndustry NewsVerastemKRAS G12Dpancreatic cancerVS-7375oncologyhttps://pharmadigest.net/en/articles/2026-10-16-gilead-vir-dual-masked-t-cell-engagers/https://pharmadigest.net/en/articles/2026-10-16-gilead-vir-dual-masked-t-cell-engagers/Vir will discover, design and optimize three T-cell engagers against solid-tumor antigens on its dual-masked PRO-XTEN platform; Gilead holds exclusive rights to nominate candidates and then develops and commercializes them. Vir receives $90M up front ($65M cash plus a $25M equity investment) and $45M in near-term preclinical milestones. Up to $1.74B in development, regulatory and commercial milestones and tiered royalties could follow.Fri, 16 Oct 2026 00:00:00 GMTIndustry NewsGileadVir BiotechnologyT-cell engagermasked TCEoncologyhttps://pharmadigest.net/en/articles/2026-10-16-zealand-generate-multispecific-obesity/https://pharmadigest.net/en/articles/2026-10-16-zealand-generate-multispecific-obesity/Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection. Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third. Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.Fri, 16 Oct 2026 00:00:00 GMTIndustry NewsZealand PharmaGenerate BiomedicinesAI protein designmultispecificobesityhttps://pharmadigest.net/en/articles/2026-10-16-pfizer-enodia-sec61-inhibitors/https://pharmadigest.net/en/articles/2026-10-16-pfizer-enodia-sec61-inhibitors/Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work. The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top. It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.Fri, 16 Oct 2026 00:00:00 GMTIndustry NewsPfizerEnodiaSec61Lillysmall moleculehttps://pharmadigest.net/en/articles/2026-10-16-roche-rona-alk7-rnai-obesity/https://pharmadigest.net/en/articles/2026-10-16-roche-rona-alk7-rnai-obesity/Roche gets an exclusive license to Rona Therapeutics' investigational ALK7-targeting RNAi candidate for obesity. Terms: up to $100M in upfront and near-term milestones, plus up to $1.06B in longer-term milestones and tiered royalties. The program's codename and development stage were not disclosed.Fri, 16 Oct 2026 00:00:00 GMTIndustry NewsRocheRona TherapeuticsALK7RNAiobesityhttps://pharmadigest.net/en/articles/2026-10-15-sanofi-eu-antitrust-flu-vaccine-commitments/https://pharmadigest.net/en/articles/2026-10-15-sanofi-eu-antitrust-flu-vaccine-commitments/EU antitrust regulators accepted concessions from Sanofi to close a probe into an allegedly misleading campaign that disparaged a rival flu vaccine. Because the case ended on accepted commitments, Sanofi avoids a fine. Details of the commitments are behind STAT's paywall; this summary rests on the public excerpt only.Thu, 15 Oct 2026 00:00:00 GMTIndustry NewsSanofiantitrustvaccinesEUhttps://pharmadigest.net/en/articles/2026-10-14-neurocrine-vykat-xr-prader-willi-safety-concerns/https://pharmadigest.net/en/articles/2026-10-14-neurocrine-vykat-xr-prader-willi-safety-concerns/STAT reports growing alarm among patient advocates and some experts over the perceived risks of Neurocrine's rare disease drug Vykat XR (diazoxide choline) for Prader-Willi syndrome. Earlier coverage links the concern to fluid retention, respiratory and cardiac events in post-marketing reports, though causality has not been established. Neurocrine has said it keeps a favourable benefit-risk view and is working with the FDA and patient groups.Wed, 14 Oct 2026 00:00:00 GMTIndustry NewsNeurocrineVykat XRPrader-Willi syndromedrug safetyhttps://pharmadigest.net/en/articles/2026-10-12-life-biosciences-glaucoma-reprogramming-update/https://pharmadigest.net/en/articles/2026-10-12-life-biosciences-glaucoma-reprogramming-update/Life Biosciences said three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug. No serious adverse events were reported so far. Only the public lede was readable, so dose, follow-up length and efficacy readouts are unverified here.Mon, 12 Oct 2026 00:00:00 GMTIndustry Newscellular reprogrammingglaucomaclinical updateLife Bioscienceshttps://pharmadigest.net/en/articles/2026-10-12-viatris-pacira-non-opioid-pain-acquisition/https://pharmadigest.net/en/articles/2026-10-12-viatris-pacira-non-opioid-pain-acquisition/Viatris agreed to acquire Pacira BioSciences in an all-cash deal at $36.50 per share, a premium of roughly 45% to the last close. The prize is Pacira's non-opioid products EXPAREL for post-surgical pain and ZILRETTA for knee osteoarthritis pain, plus a knee OA gene therapy candidate. Closing is expected by the end of 2026, funded mainly from cash on hand.Mon, 12 Oct 2026 00:00:00 GMTIndustry NewsM&Anon-opioid painViatrisPaciraEXPARELhttps://pharmadigest.net/en/articles/2026-10-10-argenx-vyvgart-sjogrens-phase3-failure/https://pharmadigest.net/en/articles/2026-10-10-argenx-vyvgart-sjogrens-phase3-failure/STAT reports that argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial in patients with Sjögren's disease, a chronic autoimmune disorder. STAT frames it as an unusual setback for a franchise that has mostly succeeded in label expansion; detailed data were not visible in the public lede.Sat, 10 Oct 2026 00:00:00 GMTIndustry NewsargenxVyvgartefgartigimodSjögren's diseaseFcRnhttps://pharmadigest.net/en/articles/2026-10-10-arrivent-furvent-phase3-firmonertinib-miss/https://pharmadigest.net/en/articles/2026-10-10-arrivent-furvent-phase3-firmonertinib-miss/Fierce Biotech reports that ArriVent's phase 3 FURVENT trial of the EGFR inhibitor firmonertinib missed its primary progression-free survival endpoint by blinded central review in first-line EGFR exon 20 insertion NSCLC. The higher dose showed only a modest numerical edge over platinum chemotherapy and the lower dose did numerically worse, while investigator-assessed results looked more favorable. ArriVent's shares fell sharply on the news.Sat, 10 Oct 2026 00:00:00 GMTIndustry NewsArriVentfirmonertinibEGFR exon 20NSCLCphase 3https://pharmadigest.net/en/articles/2026-10-09-roche-defand-molecular-glue-discovery-deal/https://pharmadigest.net/en/articles/2026-10-09-roche-defand-molecular-glue-discovery-deal/STAT reports Roche has signed a drug discovery deal with Chinese biotech Defand Therapeutics focused on molecular glue medicines. Only the public lede of the STAT+ article could be read, so financial terms and targets are unverified here.Fri, 09 Oct 2026 00:00:00 GMTIndustry Newsmolecular gluepartnershipRocheChina biotechtargeted protein degradationhttps://pharmadigest.net/en/articles/2026-10-09-forbion-raises-2-6-billion-fund/https://pharmadigest.net/en/articles/2026-10-09-forbion-raises-2-6-billion-fund/STAT reports European venture firm Forbion has raised $2.6 billion, its largest fundraise to date. It is described as one of the largest in the region in recent years; fund structure and allocation were not visible in the public lede.Fri, 09 Oct 2026 00:00:00 GMTIndustry Newsventure capitalForbionfinancingEuropehttps://pharmadigest.net/en/articles/2026-10-09-merck-keytruda-subcutaneous-dutch-court-halt/https://pharmadigest.net/en/articles/2026-10-09-merck-keytruda-subcutaneous-dutch-court-halt/STAT reports a Dutch court ordered Merck to stop manufacturing and marketing its subcutaneous Keytruda formulation in several European countries. Only the public lede was readable, so the plaintiff, grounds and scope are unverified here.Fri, 09 Oct 2026 00:00:00 GMTIndustry NewsKeytrudasubcutaneouspatentMerckEuropehttps://pharmadigest.net/en/articles/2026-10-08-caribou-biosciences-wind-down-car-t/https://pharmadigest.net/en/articles/2026-10-08-caribou-biosciences-wind-down-car-t/STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma. Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale. Only the public STAT+ summary was available, so details beyond that are unverified.Thu, 08 Oct 2026 00:00:00 GMTIndustry NewsCAR-Tcell therapywind-downlymphomafinancinghttps://pharmadigest.net/en/articles/2026-10-08-astrazeneca-kendall-square-boston-rd-site/https://pharmadigest.net/en/articles/2026-10-08-astrazeneca-kendall-square-boston-rd-site/AstraZeneca opened a new R&D site in Boston's Kendall Square, marking a $1 billion investment. STAT frames the opening against a backdrop of heavy dealmaking with Chinese biotechs and uncertainty in the US biotech hub. Only the public STAT+ summary was available; site scope and headcount are not verified.Thu, 08 Oct 2026 00:00:00 GMTIndustry NewsAstraZenecaBostonR&D investmentChina dealmakinghttps://pharmadigest.net/en/articles/2026-10-07-lycia-lytac-extracellular-degrader-ipo-filing/https://pharmadigest.net/en/articles/2026-10-07-lycia-lytac-extracellular-degrader-ipo-filing/Lycia Therapeutics filed publicly for an IPO of up to $100M on Nasdaq under LYCA, after a confidential filing in July. Its LYTAC platform, from Carolyn Bertozzi's lab, shuttles extracellular proteins to the lysosome for degradation. Lead LCA-0061 degrades IgE for food allergy and is in Phase 1; LCA-0321 targets Graves' disease autoantibodies.Wed, 07 Oct 2026 00:00:00 GMTIndustry NewsIPOLYTACextracellular degradersIgEautoimmunehttps://pharmadigest.net/en/articles/2026-10-07-genentech-alector-al050-gcase-parkinsons-license/https://pharmadigest.net/en/articles/2026-10-07-genentech-alector-al050-gcase-parkinsons-license/Alector licensed AL050, a preclinical brain-penetrant engineered GCase enzyme replacement therapy for Parkinson's disease, to Genentech. The deal brings $100M upfront, up to $1.17B in milestones and tiered royalties; Genentech takes development, manufacturing and commercialization. Alector keeps its Brain Carrier platform, and the cash extends its runway into 2029.Wed, 07 Oct 2026 00:00:00 GMTIndustry NewslicensingParkinson's diseaseGCaseblood-brain barrierenzyme replacementhttps://pharmadigest.net/en/articles/2026-10-07-merck-scibrunch-kras-g12d-spr2015-license/https://pharmadigest.net/en/articles/2026-10-07-merck-scibrunch-kras-g12d-spr2015-license/Merck took exclusive worldwide rights to SPR2015, an oral preclinical KRAS G12D (ON) inhibitor from Shanghai-based SciBrunch. SciBrunch gets $400M upfront, with total potential value of $2.13B across milestones. The deal has already closed.Wed, 07 Oct 2026 00:00:00 GMTIndustry NewslicensingKRAS G12DChina out-licensingoncologyhttps://pharmadigest.net/en/articles/2026-10-06-csl-alentis-lixudebart-claudin-1-partnership/https://pharmadigest.net/en/articles/2026-10-06-csl-alentis-lixudebart-claudin-1-partnership/CSL will pay $355 million upfront, plus up to $1.2 billion in commercial milestones, to co-develop and co-commercialize the anti-Claudin-1 antibody lixudebart. Profits split 55% CSL and 45% Alentis; CSL funds the ongoing phase 2 in ANCA-associated vasculitis with rapidly progressive glomerulonephritis and a phase 3. Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis are also planned.Tue, 06 Oct 2026 00:00:00 GMTIndustry NewsClaudin-1fibrosisco-developmentnephrologyprofit sharehttps://pharmadigest.net/en/articles/2026-10-06-genmab-rina-s-ovarian-phase2-vs-elahere/https://pharmadigest.net/en/articles/2026-10-06-genmab-rina-s-ovarian-phase2-vs-elahere/Genmab reported phase 2 RAINFOL-01 data for the ADC rinatabart sesutecan (Rina-S): a 45.9% confirmed response rate in 109 heavily pretreated patients. Median progression-free survival was 9.5 months; TD Cowen analysts called that clearly better than the 5.6 months cited for AbbVie's Elahere. Activity was reported regardless of prior Elahere treatment and in patients with low or no FRα expression.Tue, 06 Oct 2026 00:00:00 GMTIndustry NewsADCovarian cancerfolate receptor alphaRina-Scompetitive landscapehttps://pharmadigest.net/en/articles/2026-10-06-lilly-jaypirca-first-line-cll-approval/https://pharmadigest.net/en/articles/2026-10-06-lilly-jaypirca-first-line-cll-approval/The FDA approved Jaypirca (pirtobrutinib) for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. It moves the non-covalent BTK inhibitor from later-line use into the first-line setting.Tue, 06 Oct 2026 00:00:00 GMTIndustry NewsBTK inhibitorpirtobrutinibCLLFDA approvallabel expansionhttps://pharmadigest.net/en/articles/2026-10-06-shionogi-intrabio-acquisition-aqneursa/https://pharmadigest.net/en/articles/2026-10-06-shionogi-intrabio-acquisition-aqneursa/Shionogi will acquire Austin-based IntraBio for $2 billion in cash, making it a subsidiary of its US arm. The prize is Aqneursa, an oral therapy approved for Niemann-Pick disease type C and, since, for ataxia-telangiectasia. Closing is expected in November–December 2026.Tue, 06 Oct 2026 00:00:00 GMTIndustry NewsM&Arare diseaseNiemann-Pick type Cataxia-telangiectasiaAqneursahttps://pharmadigest.net/en/articles/2026-10-05-jcr-italfarmaco-izcargo-jr-141-license/https://pharmadigest.net/en/articles/2026-10-05-jcr-italfarmaco-izcargo-jr-141-license/JCR Pharmaceuticals signed an exclusive license with Italfarmaco for JR-141 (pabinafusp alfa; Izcargo in Japan) in the US, Europe and Latin America. The blood-brain-barrier-penetrating enzyme replacement therapy targets Hunter syndrome (MPS II); it was launched in Japan in 2021 and is in Phase 3. Italfarmaco will commercialize after approvals; JCR keeps manufacturing and receives upfront, milestone, royalty and supply revenue. Amounts were not disclosed.Mon, 05 Oct 2026 00:00:00 GMTIndustry NewsHunter syndromeMPS IIblood-brain barrierenzyme replacement therapyexclusive licensehttps://pharmadigest.net/en/articles/2026-10-05-summit-astrazeneca-daiichi-ivonescimab-datroway-tnbc-collaboration/https://pharmadigest.net/en/articles/2026-10-05-summit-astrazeneca-daiichi-ivonescimab-datroway-tnbc-collaboration/Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC). It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer. The companies will share trial costs, and each retains development and commercial rights to its own drug.Mon, 05 Oct 2026 00:00:00 GMTIndustry NewsivonescimabDatrowayTROP2 ADCPD-1xVEGFtriple-negative breast cancerhttps://pharmadigest.net/en/articles/2026-10-04-boehringer-zealand-survodutide-phase3-tolerability/https://pharmadigest.net/en/articles/2026-10-04-boehringer-zealand-survodutide-phase3-tolerability/Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3. Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out. Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question. It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.Sun, 04 Oct 2026 00:00:00 GMTIndustry NewsobesityGLP-1/glucagonsurvodutidephase 3competitive landscapehttps://pharmadigest.net/en/articles/2026-10-04-novo-orbis-oral-macrocycle-cardiometabolic-deal/https://pharmadigest.net/en/articles/2026-10-04-novo-orbis-oral-macrocycle-cardiometabolic-deal/Orbis Medicines signed a multi-target discovery and license deal with Novo Nordisk worth up to $1.4B in upfront and milestone payments plus tiered royalties. Novo also takes a strategic equity stake in the private Copenhagen company; this is Orbis's first pharma partnership. The work uses Orbis's AI-enabled nGen platform to make macrocycles aimed at turning injectable cardiometabolic therapies into orals. Orbis reported preclinical oral bioavailability up to 18%; targets and disease areas beyond cardiometabolic were not disclosed.Sun, 04 Oct 2026 00:00:00 GMTIndustry Newsmacrocycleoral peptidecardiometabolicplatform dealAI drug discoveryhttps://pharmadigest.net/en/articles/2026-10-03-novartis-abogen-mrna-tce/https://pharmadigest.net/en/articles/2026-10-03-novartis-abogen-mrna-tce/Novartis gains worldwide exclusive rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager produced in vivo to reset B cells in autoimmune disease. The package is $575M upfront plus up to $7.2B in milestones (up to $7.8B in total) and royalties. Novartis also receives options on other Abogen RNA-based programs. The deal follows Novartis pausing an autoimmune CAR-T program after three deaths.Sat, 03 Oct 2026 00:00:00 GMTIndustry Newsmrnat-cell engagerautoimmunelicensingin vivohttps://pharmadigest.net/en/articles/2026-10-02-sanofi-regeneron-alliance-expansion-four-antibodies/https://pharmadigest.net/en/articles/2026-10-02-sanofi-regeneron-alliance-expansion-four-antibodies/Sanofi and Regeneron expanded their alliance with $1 billion upfront and up to $7 billion in development, regulatory and commercial milestones. The deal adds four antibodies: clinical-stage long-acting IL-13 REGN20423, a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibodies against IL-4 pathway targets. Regeneron leads R&D, Sanofi leads global commercialization, and costs and profits split 50:50.Fri, 02 Oct 2026 00:00:00 GMTIndustry NewsSanofiRegeneronDupixentimmunologyantibodieshttps://pharmadigest.net/en/articles/2026-10-02-lilly-eloratzp-amylin-tirzepatide-phase2b/https://pharmadigest.net/en/articles/2026-10-02-lilly-eloratzp-amylin-tirzepatide-phase2b/EloraTZP combines the amylin agonist eloralintide with tirzepatide; in adults with obesity and type 2 diabetes it beat tirzepatide alone on weight loss and A1C at 48 weeks, with up to 23.3% weight loss at the top dose. Discontinuations due to adverse events were higher in the combination arms, mostly GI-related during dose escalation, which raises tolerability questions. Lilly plans to start phase 3 in the fourth quarter of 2026.Fri, 02 Oct 2026 00:00:00 GMTIndustry NewsEli LillyobesityamylintirzepatideEASDhttps://pharmadigest.net/en/articles/2026-10-01-novo-hengrui-oral-glp1-gip-license/https://pharmadigest.net/en/articles/2026-10-01-novo-hengrui-oral-glp1-gip-license/Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties. The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.Thu, 01 Oct 2026 00:00:00 GMTIndustry NewsobesityGLP-1/GIPoralin-licensingChinahttps://pharmadigest.net/en/articles/2026-10-01-astrazeneca-summit-ivonescimab-adc-investment/https://pharmadigest.net/en/articles/2026-10-01-astrazeneca-summit-ivonescimab-adc-investment/AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted). The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.Thu, 01 Oct 2026 00:00:00 GMTIndustry NewsivonescimabPD-1/VEGFantibody-drug conjugateCLDN18.2oncologyhttps://pharmadigest.net/en/articles/2026-10-01-merck-recarbrio-us-withdrawal/https://pharmadigest.net/en/articles/2026-10-01-merck-recarbrio-us-withdrawal/Merck is discontinuing Recarbrio, its reserve-use antibiotic combination, in the U.S. as part of a portfolio review, and says the move is unrelated to safety or quality. Approved seven years ago for hospital-acquired pneumonia and complicated urinary and abdominal infections with few options, it leaves Merck with only mature antibiotics and, per trade reports, no antibacterial programs in Phase II or later.Thu, 01 Oct 2026 00:00:00 GMTIndustry NewsantibioticRecarbrioantimicrobial resistanceportfolio reviewhttps://pharmadigest.net/en/articles/2026-10-01-roche-emugrobart-obesity-discontinued/https://pharmadigest.net/en/articles/2026-10-01-roche-emugrobart-obesity-discontinued/Roche ended obesity development of emugrobart (GYM329), an anti-latent-myostatin sweeping antibody meant to preserve muscle alongside GLP-1 therapy, after a Phase 2 GYMINDA interim analysis made meaningful weight loss unlikely. Rights revert to Chugai, which is preparing to resume development in spinal muscular atrophy and is open to out-licensing; the antibody had already missed in SMA and FSHD trials in March.Thu, 01 Oct 2026 00:00:00 GMTIndustry NewsobesitymyostatinantibodydiscontinuationSMAhttps://pharmadigest.net/en/articles/2026-09-30-mirum-brelovitug-hepatitis-delta-phase3/https://pharmadigest.net/en/articles/2026-09-30-mirum-brelovitug-hepatitis-delta-phase3/The Phase 3 portion of AZURE-1 met its primary endpoint at week 24: roughly half of treated patients responded on either the weekly or four-weekly subcutaneous regimen, versus none on delayed treatment. No grade 3 or higher or serious adverse events were reported through week 24. A second Phase 3, AZURE-4, is expected in Q4, with a filing possible in the first half of next year.Wed, 30 Sep 2026 00:00:00 GMTIndustry Newshepatitis deltaantibodyphase 3HDVhttps://pharmadigest.net/en/articles/2026-09-30-tolerance-tanabe-il33-antibody-license/https://pharmadigest.net/en/articles/2026-09-30-tolerance-tanabe-il33-antibody-license/Tolerance Bio takes global development rights and ex-Japan commercial rights to Tanabe Pharma's clinical-stage anti-IL-33 antibody MT-2990, renamed TLB-33, in a deal with milestones that could reach $560 million. The antibody has been tested in more than 150 patients across five trials; Tolerance plans a Phase 2 study on preserving thymic function and immune resilience.Wed, 30 Sep 2026 00:00:00 GMTIndustry NewsIL-33antibodythymusin-licensinghttps://pharmadigest.net/en/articles/2026-09-30-genentech-earendil-ai-bispecific-collaboration/https://pharmadigest.net/en/articles/2026-09-30-genentech-earendil-ai-bispecific-collaboration/Genentech will pay Earendil Labs $55 million upfront, with up to about $1.445 billion in development, regulatory and sales milestones, plus tiered royalties. Earendil leads antibody discovery and early clinical work on pre-agreed target pairs using its AI antibody-generation platform; Genentech takes over global development and commercialization.Wed, 30 Sep 2026 00:00:00 GMTIndustry Newsbispecific antibodyAI drug discoveryoncologycollaboration